{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T04:07:24Z","timestamp":1784866044588,"version":"3.55.0"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:00:00Z","timestamp":1732233600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Research has indicated that the disease burden of alopecia areata (AA) in China exceeds the global average. Therefore, accurate and updated epidemiological information is crucial for policymakers. In this study, we aimed to comprehensively assess the disease burden of AA in China.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>The following four key indicators were utilized: the prevalence of cases; disability-adjusted life-years (DALYs); the age-standardized prevalence rate (ASPR); and the age-standardized DALY rate (ASDR) of AA according to the Global Burden of Disease (GBD) study 2021. We analyzed the epidemiological burden of AA in China during 2021, examined changes between 1990 and 2021, and performed a Bayesian age\u2013period\u2013cohort analysis to predict trends over the course of the next decade (2022\u20132030). Additionally, a Gaussian process regression model was applied to estimate the relationship between the gross domestic product (GDP) and the ASPR and ASDR of AA at the provincial level between 1992 and 2021.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>In 2021, the estimated number of patients with AA in China was approximately 3.49\u00a0million (95% uncertainty interval [UI], 3.37\u20133.62\u00a0million); of these patients, 1.20\u00a0million (95% UI, 1.16\u20131.25\u00a0million) were male and 2.29\u00a0million (95% UI, 2.20\u20132.37\u00a0million) were female. This large number of patients with AA resulted in a total of 114,431.25 DALYs (95% UI, 74,780.27\u2013160,318.96 DALYs). Additionally, the ASPR and ASDR were 224.61 per 100,000 population (95% UI, 216.73\u2013232.65 per 100,000 population) and 7.41 per 100,000 population (95% UI, 4.85\u201310.44 per 100,000 population), respectively; both of these rates were higher than the global averages. The most affected demographic groups were young and female individuals 25\u201339\u00a0years of age. Slight regional disparities were observed, with the northern and central regions of China bearing comparatively higher burdens. Between 1990 and 2021, the health loss and disease burden caused by AA in China remained relatively stable. The ASPR and ASDR of AA increased with the GDP when the annual GDP was less than 2 trillion Chinese yuan; however, a downward trend was observed as the GDP surpassed 2 trillion Chinese yuan. A slight upward trend in the disease burden of AA in China is predicted to occur over the next decade.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>AA continues to be a public health concern in China that shows no signs of declining. Targeted efforts for young individuals and females are necessary because they experience a disproportionately high burden of AA.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cm9.0000000000003373","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T07:00:50Z","timestamp":1732258850000},"page":"318-324","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Burden of alopecia areata in China, 1990\u20132021: Global Burden of Disease Study 2021"],"prefix":"10.1097","volume":"138","author":[{"given":"Xiangqian","family":"Li","sequence":"first","affiliation":[{"name":"Department of Dermatology, Peking University People\u2019s Hospital, Beijing 100044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huixin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology and Biostatistics, Peking University People\u2019s Hospital, Beijing 100044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhui","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology and Biostatistics, Peking University People\u2019s Hospital, Beijing 100044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qijiong","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Public Health and Preventive Medicine, School of Medicine, Jinan University, Guangzhou, Guangdong 510632, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Yin","sequence":"additional","affiliation":[{"name":"National Center for Chronic and Non-Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 100050, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Wang","sequence":"additional","affiliation":[{"name":"National Center for Chronic and Non-Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 100050, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzhong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Peking University People\u2019s Hospital, Beijing 100044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlei","family":"Qi","sequence":"additional","affiliation":[{"name":"National Center for Chronic and Non-Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 100050, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Peking University People\u2019s Hospital, Beijing 100044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,11,22]]},"reference":[{"key":"R1-20250519","doi-asserted-by":"crossref","first-page":"103061","DOI":"10.1016\/j.autrev.2022.103061","article-title":"The current state of knowledge of the immune ecosystem in alopecia areata","volume":"21","author":"Connell","year":"2022","journal-title":"Autoimmun Rev"},{"key":"R2-20250519","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s12016-021-08883-0","article-title":"Alopecia areata: An update on etiopathogenesis, diagnosis, and management","volume":"61","author":"Zhou","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"key":"R3-20250519","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/jid.2013.464","article-title":"Lifetime incidence risk of alopecia areata estimated at 2.1% by Rochester Epidemiology Project, 1990\u20132009","volume":"134","author":"Mirzoyev","year":"2014","journal-title":"J Invest Dermatol"},{"key":"R4-20250519","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jaad.2020.06.047","article-title":"Psychosocial and psychiatric comorbidities and health-related quality of life in alopecia areata: A systematic review","volume":"85","author":"Toussi","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"R5-20250519","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/bjd\/ljae058","article-title":"Global, regional, and national epidemiology of alopecia areata: A systematic review and modelling study","volume":"191","author":"Jeon","year":"2024","journal-title":"Br J Dermatol"},{"key":"R6-20250519","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1056\/NEJMra1103442","article-title":"Alopecia areata","volume":"366","author":"Gilhar","year":"2012","journal-title":"N Engl J Med"},{"key":"R7-20250519","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1093\/bjd\/ljad381","article-title":"Epidemiology of alopecia areata and population-wide comorbidities in Germany: Analysis of longitudinal claims data","volume":"190","author":"Augustin","year":"2024","journal-title":"Br J Dermatol."},{"key":"R8-20250519","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.jaad.2019.05.086","article-title":"Association between alopecia areata, anxiety, and depression: A systematic review and meta-analysis","volume":"88","author":"Okhovat","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"R9-20250519","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1111\/jdv.18926","article-title":"The burden of alopecia areata: A scoping review focusing on quality of life, mental health and work productivity","volume":"37","author":"Muntyanu","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R10-20250519","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jdermsci.2023.09.008","article-title":"Alopecia areata: What\u2019s new in the epidemiology, comorbidities, and pathogenesis?","volume":"112","author":"Dainichi","year":"2023","journal-title":"J Dermatol Sci"},{"key":"R11-20250519","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/1346-8138.16615","article-title":"Prevalence, comorbidities, and treatment patterns of Japanese patients with alopecia areata: A descriptive study using Japan medical data center claims database","volume":"50","author":"Campos-Alberto","year":"2023","journal-title":"J Dermatol"},{"key":"R12-20250519","doi-asserted-by":"crossref","first-page":"185","DOI":"10.12788\/cutis.0994","article-title":"Evaluating the cost burden of alopecia areata treatment: A comprehensive review for dermatologists","volume":"113","author":"Patel","year":"2024","journal-title":"Cutis"},{"key":"R13-20250519","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1001\/jamadermatol.2018.5218","article-title":"Association of out-of-pocket health care costs and financial burden for patients with alopecia areata","volume":"155","author":"Li","year":"2019","journal-title":"JAMA Dermatol"},{"key":"R14-20250519","doi-asserted-by":"crossref","first-page":"e13958","DOI":"10.1111\/eci.13958","article-title":"Global, regional and national burden of alopecia areata and its associated diseases, 1990-2019: A systematic analysis of the Global Burden of Disease Study 2019","volume":"53","author":"Jang","year":"2023","journal-title":"Eur J Clin Invest"},{"key":"R15-20250519","first-page":"668","article-title":"Alopecia areata in China: A survey on prevalence in 6 cities (in Chinese)","author":"Wang","year":"2009","journal-title":"Chin J Dermatol"},{"key":"R16-20250519","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/S0140-6736(24)00757-8","article-title":"Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371\u00a0diseases and injuries in 204 countries and territories and 811\u00a0subnational locations, 1990-2021: A systematic analysis for the Global Burden of Disease Study 2021","volume":"403","year":"2024","journal-title":"Lancet"},{"key":"R17-20250519","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/bimj.201500263","article-title":"Projecting the future burden of cancer: Bayesian age-period-cohort analysis with integrated nested Laplace approximations","volume":"59","author":"Riebler","year":"2017","journal-title":"Biom J"},{"key":"R18-20250519","doi-asserted-by":"crossref","first-page":"101174","DOI":"10.1016\/j.arr.2020.101174","article-title":"A research agenda for ageing in China in the 21st century (2nd edition): Focusing on basic and translational research, long-term care, policy and social networks","volume":"64","author":"Fang","year":"2020","journal-title":"Ageing Res Rev"},{"key":"R19-20250519","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/jdv.19768","article-title":"European expert consensus statement on the systemic treatment of alopecia areata","volume":"38","author":"Rudnicka","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R20-20250519","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jaad.2019.08.032","article-title":"Epidemiology of alopecia areata, ophiasis, totalis, and universalis: A systematic review and meta-analysis","volume":"82","author":"Lee","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"R21-20250519","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jaut.2018.12.001","article-title":"Alopecia areata: A multifactorial autoimmune condition","volume":"98","author":"Simakou","year":"2019","journal-title":"J Autoimmun"},{"key":"R22-20250519","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1365-2133.2004.05915.x","article-title":"The genetic epidemiology of alopecia areata in China","volume":"151","author":"Yang","year":"2004","journal-title":"Br J Dermatol"},{"key":"R23-20250519","doi-asserted-by":"crossref","first-page":"A271","DOI":"10.1016\/j.autrev.2009.11.014","article-title":"Stress and autoimmunity","volume":"9","author":"Stojanovich","year":"2010","journal-title":"Autoimmun Rev"},{"key":"R24-20250519","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000507296","article-title":"Alopecia areata and toxic metals","volume":"6","author":"Pigatto","year":"2020","journal-title":"Skin Appendage Disord"},{"key":"R25-20250519","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1007\/s00403-023-02721-3","article-title":"Associations between season, climate, and pediatric alopecia areata flares in Providence, Rhode Island","volume":"315","author":"Zhang","year":"2023","journal-title":"Arch Dermatol Res"},{"key":"R26-20250519","first-page":"409","article-title":"Gender differences in alopecia areata","volume":"13","author":"Lundin","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"R27-20250519","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/ajd.14126","article-title":"Incidence and prevalence of alopecia areata in the Australian primary care setting: A retrospective analysis of electronic health record data","volume":"64","author":"Sinclair","year":"2023","journal-title":"Australas J Dermatol"},{"key":"R28-20250519","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jamadermatol.2023.0002","article-title":"Trends in prevalence and incidence of alopecia areata, alopecia totalis, and alopecia universalis among adults and children in a us employer-sponsored insured population","volume":"159","author":"Mostaghimi","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"3 Pt B","key":"R29-20250519","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.jid.2021.06.008","article-title":"Sex bias and autoimmune diseases","volume":"142","author":"Xing","year":"2022","journal-title":"J Invest Dermatol"},{"key":"R30-20250519","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1097\/CM9.0000000000002360","article-title":"Sex differences in systemic lupus erythematosus (SLE): An inception cohort of the Chinese SLE Treatment and Research Group (CSTAR) registry XVII","volume":"135","author":"Gui","year":"2022","journal-title":"Chin Med J"},{"key":"R31-20250519","doi-asserted-by":"crossref","first-page":"102193","DOI":"10.1016\/j.eclinm.2023.102193","article-title":"Global, regional, and national incidence of six major immune-mediated inflammatory diseases: Findings from the global burden of disease study 2019","volume":"64","year":"2023","journal-title":"EClinicalMedicine"},{"key":"R32-20250519","doi-asserted-by":"crossref","first-page":"16039","DOI":"10.1038\/nrdp.2016.39","article-title":"Systemic lupus erythematosus","volume":"2","author":"Kaul","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"R33-20250519","doi-asserted-by":"crossref","first-page":"17011","DOI":"10.1038\/nrdp.2017.11","article-title":"Alopecia areata","volume":"3","author":"Pratt","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"R34-20250519","doi-asserted-by":"crossref","first-page":"e2336120","DOI":"10.1001\/jamanetworkopen.2023.36120","article-title":"Autoimmune and autoinflammatory connective tissue disorders following COVID-19","volume":"6","author":"Lim","year":"2023","journal-title":"JAMA Netw Open"},{"key":"R35-20250519","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s40257-017-0312-y","article-title":"Evaluation of the relationship between alopecia areata and viral antigen exposure","volume":"19","author":"Richardson","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"R36-20250519","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsy111","article-title":"The risk of alopecia areata and other related autoimmune diseases in patients with sleep disorders: A Korean population-based retrospective cohort study","volume":"41","author":"Seo","year":"2018","journal-title":"Sleep"},{"key":"R37-20250519","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s11845-020-02410-4","article-title":"Role of adiponectin and leptin in patients with alopecia areata with scalp hair loss","volume":"190","author":"Serarslan","year":"2021","journal-title":"Ir J Med Sci"},{"key":"R38-20250519","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1126\/science.ade0113","article-title":"The link between obesity and autoimmunity","volume":"379","author":"Matarese","year":"2023","journal-title":"Science"},{"key":"R39-20250519","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","article-title":"Two phase 3 trials of baricitinib for alopecia areata","volume":"386","author":"King","year":"2022","journal-title":"N Engl J Med"},{"key":"R40-20250519","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-2","article-title":"Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: A randomised, double-blind, multicentre, phase 2b-3 trial","volume":"401","author":"King","year":"2023","journal-title":"Lancet"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000003373","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T14:01:00Z","timestamp":1747663260000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000003373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,22]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000003373","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,22]]},"assertion":[{"value":"2024-06-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}